Capricor Therapeutics, Inc. (CAPR)
| Market Cap | 1.49B +224.0% |
| Revenue (ttm) | n/a |
| Net Income | -114.59M |
| EPS | -2.32 |
| Shares Out | 57.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 773,705 |
| Open | 25.11 |
| Previous Close | 25.04 |
| Day's Range | 25.00 - 26.12 |
| 52-Week Range | 4.30 - 40.37 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 54.11 (+109.73%) |
| Earnings Date | May 12, 2026 |
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CAPR stock is "Strong Buy." The 12-month stock price target is $54.11, which is an increase of 109.73% from the latest price.
News
Caprock Announces Proposed Private Placement
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce a proposed non-brokered private placement offering of up to 6,...
Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock", or the "Company") is pleased to announce high-grade assay results for the final three drill holes from...
Capricor Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
HOPE-3 trial data supports regulatory progress for deramiocel in Duchenne muscular dystrophy, with a PDUFA date in August 2026. Commercial launch preparations are underway, including manufacturing scale-up and payer engagement, while legal action with NS Pharma proceeds independently.
Capricor Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announ...
Capricor Therapeutics Slides: Corporate presentation
Capricor Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 29, 2026.
Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Capricor Therapeutics (CAPR) to $38 from $43 and keeps a Buy rating on the shares. Roth notes that while…
Capricor Therapeutics Earnings Call Transcript: Q1 2026
BLA for deramiocel is under FDA review with a PDUFA date of August 22, 2026, and commercial launch preparations are accelerating amid a legal dispute with NS Pharma over distribution rights and pricing. Strong HOPE-3 data support approval prospects, and financials show ample runway into late 2027.
Capricor Therapeutics Earnings release: Q1 2026
Capricor Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Capricor Therapeutics Quarterly report: Q1 2026
Capricor Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb ...
Capricor files suit against NS Pharma over Deramiocel distribution deal
Capricor Therapeutics (CAPR) announced that it has filed a lawsuit against Nippon Shinyaku (NPNKF) and its U.S. subsidiary, NS Pharma, over the parties’ U.S. distribution agreement for Deramiocel, Cap...
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative...
Capricor Therapeutics Proxy statement: Proxy filing
Capricor Therapeutics filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Capricor Therapeutics Proxy statement: Proxy filing
Capricor Therapeutics filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Capricor Therapeutics price target raised to $43 from $41 at Roth Capital
Roth Capital raised the firm’s price target on Capricor Therapeutics (CAPR) to $43 from $41 and keeps a Buy rating on the shares. The firm is updating its model while…
Capricor selloff today a buying opportunity, says Roth Capital
Roth Capital analyst Boobalan Pachaiyappan recommends buying shares of Capricor Therapeutics (CAPR) on today’s selloff. The 8% pullback is a “transient, healthy and short-lived market correction” foll...
Capricor Therapeutics price target raised to $51 from $48 at Alliance Global
Alliance Global raised the firm’s price target on Capricor Therapeutics (CAPR) to $51 from $48 and keeps a Buy rating on the shares. Capricor delivered an upbeat Q4 update, highlighting…
Capricor Therapeutics price target raised to $63 from $50 at B. Riley
B. Riley raised the firm’s price target on Capricor Therapeutics (CAPR) to $63 from $50 and keeps a Buy rating on the shares. Following Q1 results and updated Phase 3…
Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler
Piper Sandler raised the firm’s price target on Capricor Therapeutics (CAPR) to $58 from $45 and keeps an Overweight rating on the shares. The firm notes Capricor ended 2025 with…
Capricor Therapeutics Earnings Call Transcript: Q4 2025
BLA for Deramiocel accepted by FDA with PDUFA date set for August 2026, following strong HOPE-3 trial results showing efficacy in DMD. Cash position is robust at $318M, with manufacturing expansion and commercial launch preparations underway.
Capricor Therapeutics Annual report: Q4 2025
Capricor Therapeutics has published its Q4 2025 annual report on March 12, 2026.
Capricor Therapeutics Earnings release: Q4 2025
Capricor Therapeutics released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Capricor Therapeutics reports Q4 EPS (62c), consensus (55c)
Cash, cash equivalents and marketable securities totaled approximately $318.1M as of December 31, 2025, compared to approximately $151.5M as of December 31, 2024. “Capricor enters 2026 with important ...
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare dise...
Capricor announces additional analyses, outcomes from Phase 3 HOPE-3 trial
Capricor Therapeutics (CAPR) announced additional analyses and new functional outcomes data from the Phase 3 HOPE-3 clinical trial of Deramiocel in Duchenne muscular dystrophy, DMD, which were present...